Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Fulgent Genetics ( (FLGT) ) is now available.
On August 1, 2025, Fulgent Genetics announced its financial results for the second quarter of 2025, reporting a 16% year-over-year growth in core revenue to $81.7 million. Despite a GAAP loss of $19.0 million, the company raised its full-year core revenue guidance to $320 million, reflecting strong momentum and strategic progress in its laboratory services and therapeutic development businesses.
The most recent analyst rating on (FLGT) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
The stock score is primarily impacted by financial performance challenges, with operational inefficiencies and cash flow issues being significant concerns. Technical analysis indicates a bearish trend, and valuation metrics are unfavorable. Despite some positive developments highlighted in the earnings call, the overall outlook remains cautious.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
Fulgent Genetics is a technology-based company with a well-established laboratory services business and a therapeutic development business. The company provides technical laboratory and testing services, along with professional interpretation of laboratory results by licensed physicians. Fulgent is also focused on developing drug candidates for treating a broad range of cancers through a novel nanoencapsulation and targeted therapy platform.
Average Trading Volume: 286,906
Technical Sentiment Signal: Strong Sell
Current Market Cap: $523M
For detailed information about FLGT stock, go to TipRanks’ Stock Analysis page.